After outlining the research and development process, drug resistance, and safety of BCL-2 inhibitors above, we review the current application status of BCL-2 inhibitors in various hematologic malignancies and their combined efficacy with immunotherapy to improve their efficacy. This evidence concerns the gene BCL2 and hematologic disorder.